BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808
· Study explores potential in solid tumors and cutaneous T-cell lymphoma · BI-1808 is one of three BioInvent drug candidates in clinical development Lund, Sweden – April 7, 2021 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. “FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting